Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishentongluo is a Traditional Chinese Medicine (TCM) therapy developed by the Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, for the treatment of diabetic kidney disease (DKD). The therapy is based on the TCM principles of tonifying the kidney (Yishen) and dredging the collaterals (Tongluo). It typically involves the use of specific herbal prescriptions tailored to the disease stage, such as Baoshentongluo Xiaobai (focused on reducing proteinuria) and Baoshentongluo Xizhuo (focused on clearing metabolic waste or 'turbidity'). Clinical evaluation of Yishentongluo therapy often involves its use as an add-on to standard-of-care treatments like ACE inhibitors or ARBs to further improve renal function, reduce urinary albumin excretion, and slow the progression of kidney damage in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yishentongluo.